The best investment for some biotechs in 2016 was in themselves. Many biopharmaceutical companies bought back significant numbers of shares this year. But which of these biotech buybacks holds the potential to provide the biggest bang for the buck for investors? Here’s why AbbVie, Celgene, and Gilead Sciences stand at the top of the list.
